ArticleInternational journal of legal medicine2026
Optimization of DNA collection card workflows on the RapidHIT™ ID instrument.
Article in International journal of legal medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
The RapidHIT™ ID System, enables CODIS eligible STR profile generation from reference samples in approximately 90 minutes. While initially optimized for buccal swabs, DNA collection cards, both treated (Nucleic-card™ and EasiCollect™) and untreated (Bode Buccal DNA Collector™), offer alternatives for collection and storage of reference samples. This study evaluated the performance of these cards using ACE GlobalFiler™ Express cartridges across a range of potentially impactful scenarios, including assessment of varying punch sizes, contamination control measures, treated versus untreated collection cards, sample placement within the cartridge, and impact of varying storage times on the collection cards. Results from cross-contamination testing confirmed no detectable contamination between samples, and a 6 mm punch size yielded the highest first-pass success rate and profile quality. Treated cards showed consistent performance during initial runs, regardless of whether they were processed wet or dry. For reruns, the EasiCollect™ cards on average produced higher overall signal when the wetting protocol was used. The untreated Bode card showed greater signal consistency when used dry, while wet treatment improved initial success rates. Proteinase K treatment enhanced DNA recovery from samples aged up to three years. Collectively, these findings provide practical, evidence-based guidelines for implementing DNA collection card-based workflows on the RapidHIT™ ID system, supporting its application across varied forensic and operational environments.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.